HIGHBuilt-inProduct / Revenue mix
TAVALISSE
“10-K Item 1: 'In 2025, we recognized $158.8 million of TAVALISSE net product sales, a 51.6% increase compared to $104.8 million in 2024.'”
RIGL · Concentration risk · 10-K extracted
Rigel Pharmaceuticals (RIGL) concentration risks
Updated
The most significant concentration Rigel Pharmaceuticals discloses is TAVALISSE, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Rigel Pharmaceuticals’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 1 disclosed concentration
HIGH1
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06Rigel Pharmaceuticals' concentration is squarely product-based: TAVALISSE generated $158.8 million in net product sales in 2025, a 51.6% increase over the $104.8 million recorded in 2024. That growth trajectory is encouraging, but it also means Rigel's commercial results are structurally tied to a single branded product rather than a diversified portfolio — there is no disclosed spread across multiple approved therapies to cushion a setback specific to TAVALISSE, whether from competition, pricing pressure, or a safety signal. This is a structural concentration rather than a counterparty dependency: it reflects the company's current commercial-stage product mix, not reliance on any particular customer, distributor, or supplier. For an educated investor, the read-through is that Rigel's near-term equity story is largely a single-product story: the strong 51.6% growth rate is a genuine positive, but the same concentration that delivers that growth also means any deceleration, formulary loss, or competitive entrant affecting TAVALISSE specifically would disproportionately move the whole business, with no other approved product currently large enough to offset it.
For the engine’s reasoning on RIGL’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ABUS | Arbutus Biopharma Corporation | 1 | 1 | 0 | 2 |
| ABSI | Absci Corporation | 1 | 0 | 0 | 1 |
| RIGL● | Rigel Pharmaceuticals, Inc. | 1 | 0 | 0 | 1 |
| ABCL | AbCellera Biologics Inc. | 0 | 0 | 0 | 0 |
| ACHV | Achieve Life Sciences, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.